FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313397726> ?p ?o ?g. }

• W4313397726 endingPage "154614" @default.
• W4313397726 startingPage "154614" @default.
• W4313397726 abstract "Adjuvant Xuebijing therapy exhibited a protective effect on severe community-acquired pneumonia (SCAP) in previous studies. Blood inflammatory biomarkers related to the disease subtype and severity of SCAP might be associated with the effects of Xuebijing on clinical outcomes of SCAP.To investigate whether neutrophils or lymphocytes are a useful biomarker of the therapeutic effect of Xuebijing on mortality and inflammation damage index.A post hoc analysis of a randomized, placebo-controlled and double-blinded clinical trial of Xuebijing in patients with SCAP (Clinical Trial Registration: ChiCTR-TRC-13003534).We compared 28-day mortality (primary outcome) and four clinical scores (secondary outcome), including pneumonia severity index (PSI) score, sequential organ failure assessment (SOFA) score, acute physiology and chronic health evaluation II (APACHE II) score, and systemic inflammatory response syndrome (SIRS) score, according to the baseline strata of neutrophil count and lymphocyte count.A total of 675 patients were included in the analyses, of which 334 received Xuebijing and 341 received the placebo. Xuebijing was more effective in SCAP patients with higher lymphocyte counts and lower neutrophil counts. In the lymphocyte-dominated inflammation (LDI) subgroup, defined as neutrophil count <13 × 109 cells/l and lymphocyte count ≥0.65 × 109 cells/l, Xuebijing reduced 28-day mortality by 15% while mortality of the neutrophil-dominated inflammation (NDI) subgroup decreased by 4.7% (p = 0.050). There was also greater improvement in the PSI, SOFA, APACHE II, and SIRS scores following Xuebijing treatment in the LDI subgroup compared with the NDI subgroup.Xuebijing treatment shows stronger protective effects in SCAP patients with higher lymphocyte and lower neutrophil counts. Our findings may facilitate the selection of the most appropriate treatments for individual patients with SCAP, including who will receive Xuebijing injections." @default.
• W4313397726 created "2023-01-06" @default.
• W4313397726 creator A5000671812 @default.
• W4313397726 creator A5001219472 @default.
• W4313397726 creator A5021015100 @default.
• W4313397726 creator A5035348100 @default.
• W4313397726 creator A5039805283 @default.
• W4313397726 creator A5039896971 @default.
• W4313397726 creator A5041951758 @default.
• W4313397726 creator A5054821225 @default.
• W4313397726 creator A5055783509 @default.
• W4313397726 creator A5076947254 @default.
• W4313397726 creator A5085352453 @default.
• W4313397726 creator A5091897566 @default.
• W4313397726 date "2023-02-01" @default.
• W4313397726 modified "2023-10-16" @default.
• W4313397726 title "The prediction of lymphocyte count and neutrophil count on the efficacy of Xuebijing adjuvant treatment for severe community-acquired pneumonia: A post hoc analysis of a randomized controlled trial" @default.
• W4313397726 cites W2051247716 @default.
• W4313397726 cites W2299324922 @default.
• W4313397726 cites W2761146002 @default.
• W4313397726 cites W2928163040 @default.
• W4313397726 cites W2948924403 @default.
• W4313397726 cites W2981095818 @default.
• W4313397726 cites W3016997309 @default.
• W4313397726 cites W3099431845 @default.
• W4313397726 cites W3213204248 @default.
• W4313397726 cites W4200265822 @default.
• W4313397726 cites W4206677002 @default.
• W4313397726 cites W4210339089 @default.
• W4313397726 doi "https://doi.org/10.1016/j.phymed.2022.154614" @default.
• W4313397726 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36587417" @default.
• W4313397726 hasPublicationYear "2023" @default.
• W4313397726 type Work @default.
• W4313397726 citedByCount "0" @default.
• W4313397726 crossrefType "journal-article" @default.
• W4313397726 hasAuthorship W4313397726A5000671812 @default.
• W4313397726 hasAuthorship W4313397726A5001219472 @default.
• W4313397726 hasAuthorship W4313397726A5021015100 @default.
• W4313397726 hasAuthorship W4313397726A5035348100 @default.
• W4313397726 hasAuthorship W4313397726A5039805283 @default.
• W4313397726 hasAuthorship W4313397726A5039896971 @default.
• W4313397726 hasAuthorship W4313397726A5041951758 @default.
• W4313397726 hasAuthorship W4313397726A5054821225 @default.
• W4313397726 hasAuthorship W4313397726A5055783509 @default.
• W4313397726 hasAuthorship W4313397726A5076947254 @default.
• W4313397726 hasAuthorship W4313397726A5085352453 @default.
• W4313397726 hasAuthorship W4313397726A5091897566 @default.
• W4313397726 hasConcept C126322002 @default.
• W4313397726 hasConcept C142724271 @default.
• W4313397726 hasConcept C168563851 @default.
• W4313397726 hasConcept C187960798 @default.
• W4313397726 hasConcept C204787440 @default.
• W4313397726 hasConcept C27081682 @default.
• W4313397726 hasConcept C2776102371 @default.
• W4313397726 hasConcept C2776252253 @default.
• W4313397726 hasConcept C2776914184 @default.
• W4313397726 hasConcept C2777063308 @default.
• W4313397726 hasConcept C2777761686 @default.
• W4313397726 hasConcept C2777914695 @default.
• W4313397726 hasConcept C2778314733 @default.
• W4313397726 hasConcept C2778384902 @default.
• W4313397726 hasConcept C2778963024 @default.
• W4313397726 hasConcept C2781090800 @default.
• W4313397726 hasConcept C29730261 @default.
• W4313397726 hasConcept C535046627 @default.
• W4313397726 hasConcept C67761136 @default.
• W4313397726 hasConcept C71924100 @default.
• W4313397726 hasConcept C74133956 @default.
• W4313397726 hasConcept C95190672 @default.
• W4313397726 hasConceptScore W4313397726C126322002 @default.
• W4313397726 hasConceptScore W4313397726C142724271 @default.
• W4313397726 hasConceptScore W4313397726C168563851 @default.
• W4313397726 hasConceptScore W4313397726C187960798 @default.
• W4313397726 hasConceptScore W4313397726C204787440 @default.
• W4313397726 hasConceptScore W4313397726C27081682 @default.
• W4313397726 hasConceptScore W4313397726C2776102371 @default.
• W4313397726 hasConceptScore W4313397726C2776252253 @default.
• W4313397726 hasConceptScore W4313397726C2776914184 @default.
• W4313397726 hasConceptScore W4313397726C2777063308 @default.
• W4313397726 hasConceptScore W4313397726C2777761686 @default.
• W4313397726 hasConceptScore W4313397726C2777914695 @default.
• W4313397726 hasConceptScore W4313397726C2778314733 @default.
• W4313397726 hasConceptScore W4313397726C2778384902 @default.
• W4313397726 hasConceptScore W4313397726C2778963024 @default.
• W4313397726 hasConceptScore W4313397726C2781090800 @default.
• W4313397726 hasConceptScore W4313397726C29730261 @default.
• W4313397726 hasConceptScore W4313397726C535046627 @default.
• W4313397726 hasConceptScore W4313397726C67761136 @default.
• W4313397726 hasConceptScore W4313397726C71924100 @default.
• W4313397726 hasConceptScore W4313397726C74133956 @default.
• W4313397726 hasConceptScore W4313397726C95190672 @default.
• W4313397726 hasLocation W43133977261 @default.
• W4313397726 hasLocation W43133977262 @default.
• W4313397726 hasOpenAccess W4313397726 @default.
• W4313397726 hasPrimaryLocation W43133977261 @default.
• W4313397726 hasRelatedWork W2034896517 @default.
• W4313397726 hasRelatedWork W2797439816 @default.
• W4313397726 hasRelatedWork W2906081044 @default.

• next